Crinetics Pharmaceuticals, Inc. (CRNX)
After hours:
- GlobeNewswire
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 9th @ 4:30 PM ETDomestic:1-888-886-7786International:1-416-764-8658Conference ID: 71864759 Participa
- GlobeNewswire
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements m
- GuruFocus.com
Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)
Jeff Knight, the Chief Operating Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), has sold 32,359 shares of the company on March 22, 2024, according to a recent SEC filing.
